Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)

NCT05115409 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory DLBCL

Interventions

DRUG: Anti-PD-1 Antibody Plus Chidamide and Rituximab

Sponsor

Sun Yat-sen University

Collaborators

[object Object]